Back to search

University of British Columbia

Covid-19 vaccine safety in special populations

Abstract

dc:description

Post-marketing surveillance is important for COVID-19 vaccines following initial emergency approval, particularly for populations not included in pre-approval studies. This dissertation characterizes the safety of mRNA COVID-19 vaccines using post-approval surveillance data in three distinct groups: older adults (≥65 years), pediatric populations (<20 years), and individuals with autoimmune diseases. Additionally, it examines the impact of different recruitment methods on participation rates in vaccine safety surveys. Data were sourced from the Canadian National Vaccine Safety Network (CANVAS) during the pandemic and included both vaccinated and unvaccinated individuals from seven Canadian provinces and territories. The outcomes of interest were health events that prevented daily activities, resulted in school/work absenteeism, or required medical consultation. Analyses profiled adverse events and adverse events of special interest (AESIs) following each mRNA COVID-19 vaccine product and dose, and evaluated health events associated with vaccination. Among the different recruitment methods used in the CANVAS active surveillance study, technology-assisted recruitment through vaccine registries proved the most effective in reaching and retaining a large, diverse sample. Across all study populations, the most frequently reported symptoms following any dose of mRNA COVID vaccine were local and systemic symptoms, such as feeling unwell, fever, and headache, and most were self-limited and resolved within seven days. Vaccinated older adults and adolescents reported a higher frequency of health events within seven days after the second mRNA COVID-19 vaccine dose (limited to mRNA-1273 for older adults) compared to their unvaccinated counterparts. Emergency care utilization among vaccinated individuals within seven months after the first dose was similar to or lower than among unvaccinated individuals. Among individuals with autoimmune diseases, the frequency of health events was similar within a week following the co-administration of COVID-19 and influenza vaccines and the administration of the COVID-19 vaccine alone, indicating no additional risk from co-administration. This dissertation provides important evidence on the safety profiles of mRNA COVID-19 vaccines, offering valuable insights to inform vaccination policies in Canada and globally. These findings support effective communication about COVID-19 vaccine safety, helping vulnerable populations make informed decisions.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy - PhD
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Population and Public Health
Grantor dc:publisher
University of British Columbia
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Soe, Phyu Mar
Contributors dc:contributor
  • Bettinger, Julie A.
  • Naus, Monika

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/90820

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Soe, Phyu Mar. Covid-19 vaccine safety in special populations. doctoral thesis, University of British Columbia, 2025. http://hdl.handle.net/2429/90820